Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$103.68 USD

103.68
3,682,033

+0.23 (0.22%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $103.67 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (139 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark

by Zacks Equity Research

Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.

Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems

by Zacks Equity Research

Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $105.81, moving -1.56% from the previous trading session.

Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Abbott (ABT) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Abbott (ABT) stood at $103.23, denoting a -0.19% change from the preceding trading day.

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

DexCom (DXCM) Declines on Potential Competition for Stelo (revised)

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

DexCom (DXCM) Declines on Potential Competition for Stelo

by Zacks Equity Research

DexCom (DXCM) stock declined on Monday following the FDA approval of another over-the-counter glucose monitor, potentially fueling competition for Stelo.

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Abbott (ABT) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

The latest trading day saw Abbott (ABT) settling at $101.74, representing a +1% change from its previous close.

Implied Volatility Surging for Abbot Laboratories (ABT) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Abbot Laboratories (ABT) stock based on the movements in the options market lately.

Abbott (ABT) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Abbott (ABT) concluded the recent trading session at $103.95, signifying a -0.27% move from its prior day's close.

Wall Street Analysts See Abbott (ABT) as a Buy: Should You Invest?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

by Zacks Equity Research

Abbott's (ABT) share recovery in the Nutrition business buoys optimism.

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: UnitedHealth, Danaher, Abbott and Ark Restaurants

by Zacks Equity Research

UnitedHealth, Danaher, Abbott and Ark Restaurants are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for UnitedHealth, Danaher & Abbott

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Danaher Corporation (DHR) and Abbott Laboratories (ABT), as well as a micro-cap stock Ark Restaurants Corp. (ARKR).

Abbott (ABT) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips

by Zacks Equity Research

Tesla, Johnson & Johnson, Netflix, Abbott and ConocoPhillips are included in this Analyst Blog.

Sheraz Mian headshot

Q1 Earnings Season Scorecard and Fresh Analyst Reports for Tesla, JNJ & Netflix

by Sheraz Mian

Today's Research Daily features the Q1 earnings season scorecard and updated analyst reports on Tesla (TSLA), JNJ (JNJ), Netflix (NFLX) and others.

Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

PBH vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBH vs. ABT: Which Stock Is the Better Value Option?

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NOBL

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

by Zacks Equity Research

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Q1 Earnings Review

by Zacks Equity Research

Q1 Earnings Review